Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 5
  • Print publication year: 2011
  • Online publication date: October 2011

Chapter 13 - The effects of antiepileptic drugs on behavior

Summary

Postictal psychiatric phenomena are relatively frequent in patients with treatment-resistant epilepsy. This chapter reviews the most relevant clinical aspects of peri-ictal symptomatology. Ictal panic is one of the most frequently misdiagnosed symptoms in medical practice, as it is often diagnosed as a panic attack. Postictal psychiatric phenomena may be the expression of isolated psychiatric symptoms; clusters of postictal psychiatric symptoms (PPS) mimicking a depressive, anxiety or psychotic episode; postictal exacerbation in severity of interictal psychiatric symptoms and persistence of interictal symptoms into the postictal period. In contrast to postictal symptoms of depression (PSD) or PDE, postictal psychotic episodes (PIPE) can be readily prevented and treated. Prevention of PIPE is possible in patients who are found to have bilateral ictal foci in the course of a video-EEG or who are known to develop PIPE after a cluster of seizures.

References

ArroyoS, AnhutH, KuglerAR, et al; Pregabalin 1008–011 International Study Group. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia. 2004; 45: 20–7.
BakerGA, HesdonB, MarsonAG. Quality of life and behavioural outcome measures in randomized controlled trials of antiepileptic drugs: a systematic review of methodology and reporting standards. Epilepsia 2000; 41: 1357–63.
Ben-MenachemE, BitonV, JatuzisD, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007; 48: 1308–17.
BeranRG, GibsonRJ. Aggressive behaviour in intellectually challenged patients with epilepsy treated with lamotrigine. Epilepsia 1998; 39: 280–2.
BesagFMC. Behavioural effects of the new anticonvulsants. Drug Safety 2001; 24: 513–36.
BeydounA, UthmanBM, KuglerAR, et al; Pregabalin 1008–009 Study Group. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 2005; 64: 475–80.
BinnieDB. Lamotrigine. In: EngelJ, PedleyTA, eds. Epilepsy. A Comprehensive Textbook. Philadelphia, New York: Lippincott–Raven, 1997: 1531–40.
BrentDA. Overrepresentation of epileptics in a consecutive series of suicide attempters seen at a children's hospital, 1978–1983. J Am Acad Child Psychiatry 1986; 25: 242–6.
BrentDA, CrumrinePK, VarmaRR, et al. Phenobarbital treatment and major depressive disorder in children with epilepsy. Pediatrics 1987; 80: 909–17.
BrodieMJ, RichensA, YuenAW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995; 345: 476–9.
ChungS, SperlingMR, BitonV, et al; SP754 Study Group. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 2010; 51: 958–67.
CrawfordP. An audit of topiramate use in a general neurology clinic. Seizure 1998; 7: 207–11.
DalbyMA. Behavioral effects of carbamazepine. In: PenryJK, DalyDD, eds. Complex Partial Seizures and their Treatment: Advances in Neurology, Vol. 11. New York: Raven Press, 1975: 331–43.
DinkelackerV, DietlT, WidmanG, et al. Aggressive behavior of epilepsy patients in the course of levetiracetam add-on therapy: report of 33 mild to severe cases. Epilepsy Behav 2003; 4: 537–47.
DrakeME, PeruzziWT. Manic state with carbamazepine therapy of seizures. J Natl Med Assoc 1986; 78: 1105–7.
EdwardsKR, SackellaresJC, VuongA, et al. Lamotrigine monotherapy improves depressive symptoms in epilepsy: a double-blind comparison with valproate. Epilepsy Behav 2001; 2: 28–36.
EstradaG, WildrickD, PrantazelliM. Neuropsychiatric Complications of Levetiracetam in Children with Epilepsy. Abstract, American Psychiatric Association, 2002.
EttingerAB, WeisbrotDM, SaraccoJ, et al. Positive and negative psychotropic effects of lamotrigine in patients with epilepsy and mental retardation. Epilepsia 1998; 39: 874–7.
FaughtE, AyalaR, MontourisGG, LeppikIE; Zonisamide 922 Trial Group. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001; 57: 1774–9.
FerrieCD, RobinsonRO, PanaziotopoulosCP. Psychotic and severe behavioural reactions with vigabatrin: a review. Acta Neurol Scand 1996; 93: 1–8.
FittonA, GoaKL. Lamotrigine. Drugs 1995; 50: 691–713.
FrenchJA, KuglerAR, RobbinsJL, et al. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 2003; 60: 1631–7.
GillhamR, KaneK, Bryant-ComstockL, BrodieMJ. A double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health-related quality of life as an outcome measure. Seizure 2000; 9: 375–9.
GilliamF. Optimizing epilepsy management: seizure control, reduction, tolerability, and co-morbidities. Introduction. Neurology 2002; 58(Suppl. 5): 1.
GustafsonMC, RitterFJ, FrostMD, KarneyV. Behavioral and Emotional Effects of Levetiracetam in Children with Intractable Epilepsy. Abstract, American Psychiatric Association, 2002.
HalászP, KälviäinenR, Mazurkiewicz-BeldzińskaM, for the SP755 Study Group. Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial. Epilepsia 2009; 50: 443–53.
HigginsGA, BreysseN, UndzysE, et al. The anti-epileptic drug lacosamide (Vimpat) has anxiolytic property in rodents. Eur J Pharmacol 2009; 624: 1–9.
Janssen-Cilag. Topamax. Product Monogr 1996.
Kalogjera-SackellaresD, SackellaresJC. Improvement in depression associated with partial epilepsy in patients treated with lamotrigine. Epilepsy Behav 2002; 3: 510–516.
KanemotoK, TsujiT, KawasakiJ. Reexamination of interictal psychoses based on DSMIV psychosis classification and international epilepsy classification. Epilepsia 2001; 42: 98–103.
KannerAM, KozakAM, FreyM.The use of sertraline in patients with epilepsy: is it safe?Epilepsy and Behaviour 2000; 1: 100–5.
KetterTA, PostRM, TheodoreWH. Positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders. Neurology 1999; 53(Suppl. 2): 53–67.
KossoffEH, BergeyGK, FreemanJM, ViningPG. Levetiracetam psychosis in children with epilepsy. Epilepsia 2001; 42: 1611–3.
LandoltH. Serial electroencephalographic investigations during psychotic episodes in epileptic patients and during schizophrenic attacks. In: Lorentz de HaasAM, ed. Lectures on Epilepsy. Amsterdam: Elsevier, 1958: 91–131.
LeeDO, SteingardRJ, CesenaM, et al. Behavioral side effects of gabapentin in children. Epilepsia 1996; 37: 87–90.
LeppikE. Tiagabine: the safety landscape. Epilepsia 1995; 36 (Suppl. 6): 10–3.
LevinsonDF, DevinskyO. Psychiatric adverse events during vigabatrin therapy. Neurology 1999; 53: 1503–11.
LombrosoCT. Lamotrigine-induced tourettism. Neurology 1999; 52: 1191–4.
MatsuuraM. Epileptic psychoses and anticonvulsant drug treatment. J Neurol Neurosurg Psychiatry 1999; 67: 231–3.
MatsuuraM, TrimbleMR. Zonisamide and psychosis. J Epilepsy 1997; 10(2): 52–4.
McDanalCE, BolmanWM. Delayed idiosyncratic psychosis with diphenylhydantoin. JAMA 1975; 231: 1063.
MesadSM, DevinskyO. Levetiracetam Related Aggression. Abstract, American Psychiatric Association, 2002.
MiyamotoT, KohsakaM, KoyamaT. Psychotic episodes during zonisamide treatment. Seizure 2000; 9: 65–70.
MulaM, HesdorfferDC, TrimbleM, SanderJW. The role of titration schedule of topiramate for the development of depression in patients with epilepsy. Epilepsia 2009; 50: 1072–76.
MulaM, TrimbleMR, LhatooSD, SanderJW. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 2003a; 44: 659–63.
MulaM, TrimbleMR, YuenA, et al. Psychiatric adverse events during levetiracetam therapy. Neurology 2003b; 61: 704–6.
RobertsonMM, TrimbleMR, TownsendHRA. Phenomenology of depression in epilepsy. Epilepsia 1987; 28: 364–72.
SackellaresJC, LeeSI, DreifussFE. Stupor following administration of valproic acid to patients receiving other convulsant drugs. Epilepsia 1979; 20: 697–703.
SackellaresJC, RamsayRE, WilderBJ, et al. Randomized, controlled clinical trial of zonisamide as adjunctive treatment for refractory partial seizures. Epilepsia 2004; 45: 610–7.
SchapelG, ChadwickD. Tiagabine and non-convulsive status epilepticus. Seizure 1996; 5: 153–6.
SchmidtD, JacobR, LoiseauP, et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res 1993; 15: 67–73.
SchmitzB, RobertsonM, TrimbleMR. Depression and schizophrenia in epilepsy: social and biological risk factors. Epilepsy Res 1999; 35: 59–68.
SchöndienstM, WolfP. Zur Möglichkeit neurotoxischer Spätwirkungen von Valproinsäure. In: KrämerG, LaubM, eds. Valproinsäure. Berlin, Heidelberg, New York: Springer, 1992: 259–65.
TallianKB, NahataMC, LoW, TsaoCZ. Gabapentin associated with aggressive behavior in pediatric patients with seizures. Epilepsia 1996; 37: 501–2.
ThomasL, TrimbleMR, SchmitzB, RingHA. Vigabatrin and behaviour disorders: A retrospective study. Epilepsy Res 1996; 25: 21–27.
Tim Wehner, Sebastian Bauera, Hajo M. Hamera, et al. Six months of postmarketing experience with adjunctive lacosamide in patients with pharmacoresistant focal epilepsy at a tertiary epilepsy center in Germany. Epilepsy & Behavior 1997; 16(3): 423–5.
TrimbleMR, ReynoldsEH. Anticonvulsant drugs and mental symptoms: a review. Psychol Med 1976; 6: 169–78.
TrimbleMR, RuaschN, BettsT, CrawfordPM. Psychiatric symptoms after therapy with new antiepileptic drugs: psychopathological and seizure related variables. Seizure 2000; 9: 249–54.
WehnerT, BaueraS, HajoM, et al. Six months of postmarketing experience with adjunctive lacosamide in patients with pharmacoresistant focal epilepsy at a tertiary epilepsy center in Germany. Epilepsy Behav 2009; 16(3): 423–5.
WhiteJR, WalczakTS, LeppikIE, et al. Discontinuation of levetiracetam because of behavioral side effects: a case-control study. Neurology 2003; 61: 1218–21.
WolfP. 1984 The clinical syndromes of forced normalisation. Fol Psychiat Neurol Jpn 38: 187–192.
WolfP, InoueZ, Röder-WannerUU, TsaiJJ. Psychiatric complications of absence therapy and their relation to alteration of sleep. Epilepsia 1984; 25: 56–9.
WolfSM, ShinnarS, KangH, et al. Gabapentin toxicity in children manifesting as behavioral changes. Epilepsia 1995; 36: 1203–5.
ZaretBS, CohenRA.Reversible valproic acid-induced dementia: a case report. Epilepsia 1986; 27: 234–40.